Taguchi T, Sugiura M, Hamada Y, Miwa I
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Biochem Pharmacol. 1998 May 15;55(10):1667-71. doi: 10.1016/s0006-2952(98)00010-0.
Aminoguanidine (AG) is considered to be a promising compound for the treatment of diabetic complications. We examined the in vitro and in vivo formation of Schiff bases of AG with pyridoxal 5'-phosphate (PLP) and pyridoxal (PL). AG reacted in vitro far more rapidly with PLP to form a Schiff base (PLP-AG) than with PL to form another Schiff base (PL-AG). Administration of AG at 7 mM in drinking water for 18 weeks caused the formation of PLP-AG in the liver and kidney of mice (12.1 +/- 1.6 and 3.8 +/- 0.64 nmol/g of tissue, respectively, mean +/- SD, N = 6). The amount of PLP in the liver of mice AG administered was significantly lower than that of control mice (4.0 +/- 1.4 vs 17.4 +/- 1.3 nmol/g of wet tissue, mean +/- SD, N = 6). Simultaneous administration of pyridoxine (1 mM in drinking water) with AG (7 mM in drinking water) did not ameliorate the decrease in tissue PLP and caused the excess formation of PLP-AG. The results suggest that attention should be paid to the deficiency of tissue PLP in the clinical use of AG.
氨基胍(AG)被认为是一种治疗糖尿病并发症的有前景的化合物。我们研究了AG与磷酸吡哆醛(PLP)和吡哆醛(PL)在体外和体内席夫碱的形成。AG在体外与PLP反应形成席夫碱(PLP - AG)的速度比与PL反应形成另一种席夫碱(PL - AG)的速度快得多。在饮用水中给予7 mM的AG持续18周导致小鼠肝脏和肾脏中形成PLP - AG(分别为12.1±1.6和3.8±0.64 nmol/g组织,平均值±标准差,N = 6)。给予AG的小鼠肝脏中PLP的量显著低于对照小鼠(4.0±1.4对17.4±1.3 nmol/g湿组织,平均值±标准差,N = 6)。同时给予吡哆醇(饮用水中1 mM)和AG(饮用水中7 mM)并不能改善组织PLP的减少,反而导致PLP - AG的过量形成。结果表明,在AG的临床应用中应注意组织PLP的缺乏。